Skip to main content

Call for papers

Fibrosis and Cancer Intersection

We are welcoming submissions to our new collection on the intersection of fibrosis and cancer, guested edited by Mary Salvatore and Monica Pernia.

Submission Deadline: 15 April 2024

Planeterranean Diet

Submit to our new collection, "Planeterranean" Diet: Globally Extending the Health Benefits of the Mediterranean Diet, guest edited by Luigi Barrea, Salvatore Nesci, Prisco Piscitelli, Laura Soldati, and Claudia Vetrani.

Submission Deadline: 30 June 2024

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Featured section: Neuroscience

The Neuroscience section aims to encourage publications that help to reduce the gap between basic preclinical science and medical applications for the patients in the neuroscience field. Any new tool for the dissemination of results in the field can greatly help to progress in the new solutions for the neuropsychiatric patient. The section aims to promote the increase of knowledge on the subject by publishing original research. 

Read the latest articles in the Neuroscience section

Featured Research: Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis

Long COVID is a debilitating chronic condition that has affected over 100 million people globally. It is characterized by a diverse array of symptoms, including fatigue, cognitive dysfunction and respiratory problems. Studies have so far largely failed to identify genetic associations, the mechanisms behind the disease, or any common pathophysiology with other conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that present with similar symptoms. This study demonstrates the power of combinatorial analytics for stratifying heterogeneous populations in complex diseases that do not have simple monogenic etiologies.

Featured Review: Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines

Advancing personalized medicine in brain cancer relies on innovative strategies, with mRNA vaccines emerging as a promising avenue. While the initial use of mRNA vaccines was in oncology, their stunning success in COVID-19 resulted in widespread attention, both positive and negative. Regardless of politically biased opinions, which relate more to the antigenic source than form of delivery, we feel it is important to objectively review this modality as relates to brain cancer. This review provides an overview of mRNA vaccine delivery technologies, tumor antigen identification, combination therapies, and recent therapeutic outcomes, with a particular focus on brain cancer.

Articles

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Journal News

Please note that Journal of Translational Medicine is no longer considering submissions of study protocols. 

Editor Spotlight

Section: Translational Metagenomics 

Selvasankar Murugesan, Ph.D., is the Senior Research fellow from the microbiome and biomarkers discovery laboratory at Sidra Medicine, Qatar. He focuses on human microbiome-based biomarker discovery to apply in precision medicine. He is an active member of the Mexican Microbiology association (AMM). In addition, he is an Associate Editor for the Journal of Translational Medicine. He holds a Ph.D. in Pharmacology from the Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV), Mexico, where he studied the role of the gut microbiome in childhood obesity.

View the previous 'Editor Spotlights' here

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Top trending articles


Check out the most discussed articles from the previous month!

Our companion journal

Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine. 

The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.

Explore Translational Medicine Communications

Introducing new sections to Journal of Translational Medicine!

Molecular Pathology

Led by Section Editor Sarah Warren, the Molecular Pathology section aims to highlight studies that characterize human-derived biological materials, including both tissue and liquid biopsies, using molecular profiling techniques to elucidate the underlying causes of disease and impacts of therapeutic interventions. 

The Molecular Pathology section will consider studies that are preclinical or translational in nature, as well as from all stages of fundamental and applied research. The section welcomes manuscripts that describe new technology platforms that advance molecular profiling or novel computational approaches to support data analysis.

Network Medicines

Led by Section Editor Joyce Hu, the Network Medicines section is dedicated to the biology-based, integrative approach aimed at understanding the topology of complex disorders and the dynamic interplay of their various components, identifying cascades of causes and effects, listening to cross-talks among cells to suggest novel and more effective therapeutic approaches.

The section welcomes research that goes beyond descriptive observations and provides compelling recommendations of disruptive therapeutic candidates.

Translational Process

© smolaw11 / stock.adobe.comLed by Marina Boccardi, the Translational Process section welcomes contributions aimed to streamline the transition of new knowledge along the translational continuum, and boost our ability to concretely innovate clinical practice. 

The Translational Process section dedicates a space to those who tackle such challenges overcoming the boundaries of individual disciplines, and offers a new opportunity to share and accelerate the development of urgently needed methods, tools and procedures. 

Reproductive Medicine & Clinical Reproductive Sciences

© Sebastian Kaulitzki / stock.adobe.comLed by Section Editor Matteo Alessandro Avella, the Reproductive Medicine & Clinical Reproductive Science section is focused on the basic mechanisms or the translational and clinical aspects of human reproductive biology. 

The section welcomes studies on preclinical and clinical studies whose results have the potential to prevent, diagnose, and treat reproductive issues, as well as studies that describe and characterize the genes and the mechanisms regulating human reproductive biology in cell line or animal models, and reviews on existing and novel technologies.

Editor-in-Chief: Francesco Marincola, Sonata Therapeutics, USA

Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.

Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.

Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.

Franco received his M.D. from the University of Milan and completed his residency at Stanford University.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:


Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.458 - SNIP (Source Normalized Impact per Paper)
    1.544 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    84 days submission to accept (Median)

    2022 Usage 
    4,243,080 downloads
    32,614 Altmetric mentions